原发性肝癌高表达抗原GPC-3的HLA-A2限制性细胞毒性T淋巴细胞表位预测

Prediction of HLA-A2 Restricted Cytotoxic T Lymphocyte Epitope in High Expression of Tumor Antigen Glypican-3 in Primary Liver Cancer

目的预测原发性肝癌高表达抗原GPC-3的HLA-A2限制性细胞毒性T淋巴细胞(CTL)表位。方法通过国家生物技术信息中心(NCBI)数据库获取GPC-3蛋白的氨基酸序列,利用超基序、量化基序法和NetCTL数据库预测分析GPC-3的HLA-A2限制性CTL表位。结果初步筛选出GPC-3肿瘤抗原的HLA-A2限制性CTL优势表位,分别为GPC-3 102～110,155～163,169～177,229～237,281～289,319～327,326～334,367～375,522～530,564～572。结论预测出GPC-3的HLA-A2限制性CTL表位为GPC-3阳性原发性肝癌免疫靶向治疗奠定了基础。

Objective To predict the HLA-A2 restricted cytotoxic T lymphocyte （CTL） epitope in high expres- sion of tumor antigen glypican-3 （ GPC-3 ） in primary liver cancer. Methods The amino acid sequences of tumor antigen GPC-3 was obtained from National Center for Biotechnology Information （NCBI） database, and HLA-A2-restricted glypi- can-3-derived CTL epitope were predicted by using a combination of three computer algorithms of super-motif, quantita- tive motif and NetCTL databases methods. Results The predominant HLA-A2 restricted CTL epitopes predicted in the tumor antigen GPC-3 were 102-110, 155-163, 169-177, 229-237, 281-289, 319-327, 326-334, 367-375, 522-530 and 564-572. Conclusion The HLA-A2 restricted CTL epitope has been predicted in tumor antigen GPC-3, which may be used for future applications in immunotherapy of targeted therapy for primal liver cancer patients with positive tumor anti- gen glypican-3.